Dr. Gregory R. Emkey, M.D.
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Pennsylvania State University College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,182
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Pennsylvania State University College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
MA license 238905 -
Internal Medicine Physician
MA license 238905
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Reading Hospital West Reading, PA
- Penn State Health St. Joseph Reading, PA
- Wellspan Ephrata Community Hospital Ephrata, PA
- Pottstown Hospital Pottstown, PA
- Surgical Institute of Reading Wyomissing, PA
Medical groups
- Phoenix Rehabilitation and Health Services Inc (2,800 clinicians)
- Keystone Rehabilitation Systems Inc (776 clinicians)
- Reading Hospital (186 clinicians)
- Emkey Arthritis and Osteoporosis Clinic PC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,182
- Services billed
- 153,865
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 36,062 | 401 |
| Injection, romosozumab-aqqg, 1 mg | 21,210 | 30 |
| Injection, golimumab, 1 mg, for intravenous use | 13,950 | 21 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 6,175 | 13 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1,183 | 217 |
| Established patient office or other outpatient visit, 20-29 minutes | 533 | 444 |
| Established patient office or other outpatient visit, 30-39 minutes | 482 | 310 |
| Injection of drug or substance under skin or into muscle | 449 | 326 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 381 | 291 |
| Dxa bone density measurement of hip, pelvis, spine | 339 | 338 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Wyomissing, PA | 449 |
| Alendronate Sodium Other prescribers in Wyomissing, PA | 443 |
| Hydroxychloroquine Sulfate Other prescribers in Wyomissing, PA | 442 |
| Methotrexate (methotrexate sodium) Other prescribers in Wyomissing, PA | 268 |
| Duloxetine Hcl Other prescribers in Wyomissing, PA | 205 |
| Gabapentin Other prescribers in Wyomissing, PA | 186 |
| Allopurinol Other prescribers in Wyomissing, PA | 119 |
| Tramadol Hcl Other prescribers in Wyomissing, PA | 100 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Wyomissing, PA | 60 |
| Enbrel Sureclick (etanercept) Other prescribers in Wyomissing, PA | 49 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 156 payments worth $35,736 in total to this clinician.
| AbbVie Inc. | $22,619 |
|---|---|
| Amgen Inc. | $11,161 |
| Janssen Biotech, Inc. | $601 |
| UCB, Inc. | $285 |
| Ani Pharmaceuticals, Inc. | $219 |
| AstraZeneca Pharmaceuticals LP | $159 |
| Radius Health, Inc. | $132 |
| E.r. Squibb & Sons, L.l.c. | $71.51 |
| Compensation for services other than consulting (speaking, faculty) | $26,600 |
|---|---|
| Travel and Lodging | $5,700 |
| Food and Beverage | $3,266 |
| Education | $170 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,675 |
| AbbVie Inc. Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,675 |
| AbbVie Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,625 |
| AbbVie Inc. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,625 |
| AbbVie Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,625 |
| Amgen Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $2,400 |
| Amgen Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $2,000 |
| Amgen Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $1,800 |
| Amgen Inc. Feb 13, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $1,800 |
| AbbVie Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,575 |
All 22 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,625 |
| AbbVie Inc. Nov 12, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to YORK, PA · in-kind | $1,058 |
| AbbVie Inc. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,625 |
| AbbVie Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,575 |
| Amgen Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $1,800 |
| AbbVie Inc. Oct 15, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to KING OF PRUSSIA, PA · in-kind | $841 |
| Janssen Biotech, Inc. Oct 2, 2025 | Education TREMFYA · Immunology · in-kind | $77.99 |
| Ani Pharmaceuticals, Inc. Sep 3, 2025 | Education PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations · in-kind | $7.35 |
| AbbVie Inc. Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,675 |
| AbbVie Inc. Jun 25, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $1,164 |
| Amgen Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $2,000 |
| Amgen Inc. Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $600 |
| Janssen Biotech, Inc. Apr 3, 2025 | Education TREMFYA · Immunology · in-kind | $84.95 |
| AbbVie Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $2,625 |
| AbbVie Inc. Feb 26, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $854 |
| AbbVie Inc. Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,675 |
| Amgen Inc. Feb 13, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $1,800 |
| Amgen Inc. Feb 13, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $800 |
| Amgen Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $2,400 |
| Amgen Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $400 |
| Amgen Inc. Jan 27, 2025 | Travel and Lodging TAVNEOS · Inflammation · travel to MEDIA, PA · in-kind | $851 |
| AbbVie Inc. Jan 15, 2025 | Travel and Lodging SKYRIZI · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $931 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $28,993 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB SA · Completed · NCT06624228 - A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.